Overview: Geftinat is a medication that contains the active ingredient Gefitinib. It is classified as a tyrosine kinase inhibitor and is primarily used in the treatment of certain types of cancer, specifically non-small cell lung cancer (NSCLC) that has specific genetic mutations.

Active Ingredient:

• Gefitinib: This small molecule inhibitor targets the epidermal growth factor receptor (EGFR) tyrosine kinase, a protein involved in cell growth and division.

Indications: Geftinat (Gefitinib) is primarily indicated for:

1. Non-Small Cell Lung Cancer (NSCLC): It is used for the first-line treatment of locally advanced or metastatic NSCLC with activating mutations of the EGFR gene.

Mechanism of Action: Gefitinib exerts its therapeutic effects by inhibiting the activity of the EGFR tyrosine kinase. In cancer cells with activating mutations of the EGFR gene, this inhibition interferes with signaling pathways that promote cell growth and division, ultimately slowing down or inhibiting the progression of cancer.

Dosage and Administration: The dosage of Geftinat (Gefitinib) is determined by the healthcare provider based on the patient’s specific condition. It is usually taken orally in the form of tablets, typically once a day, with or without food.

Potential Side Effects: Common side effects of Gefitinib may include rash, diarrhea, nausea, fatigue, and changes in liver enzyme levels. Serious side effects may include interstitial lung disease and liver problems. Patients should promptly report any new or worsening symptoms to their healthcare provider.

Precautions:

• Regular Monitoring: Regular monitoring of liver function and lung function is recommended during treatment with Gefitinib.
• Interstitial Lung Disease (ILD): Patients should be monitored for signs and symptoms of ILD, including cough and difficulty breathing.
• Contraception: Due to potential risks to the developing fetus, effective contraception is advised during and for a certain period after treatment.

Prescription Requirement: Geftinat (Gefitinib) is available only with a prescription and should be used under the supervision of a qualified healthcare professional.

Interaction with Food: Gefitinib absorption may be affected by food, and it is generally recommended to take it on an empty stomach.

In conclusion, Geftinat (Gefitinib) is a tyrosine kinase inhibitor used in the treatment of non-small cell lung cancer with specific EGFR gene mutations. Its mechanism of action involves inhibiting key signaling pathways associated with cancer cell growth, and its use requires careful monitoring and consideration of potential side effects under the guidance of a healthcare provider.